Holen Sie sich die Stockscreener-App
1.36
0.00%
0.00
Acurx Pharmaceuticals Inc Aktie (ACXP) Neueste Nachrichten
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why - Eastern Progress
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global - Eagle-Tribune
Acurx Pharmaceuticals (NASDAQ: ACXP) May Generate Up to $2.8M Through Lincoln Park Capital Share Sales - Kalkine Media
Acurx Pharmaceuticals Q2FY26 Results: Net loss widens 4.5% to $2.3 million - scanx.trade
Transcript: Acurx Pharmaceuticals Q2 2026 Earnings Conference Call - Benzinga
Acurx Pharmaceuticals, Inc. SEC Filing (Sep 18, 2026) - Stock Titan
Acurx Pharmaceuticals files prospectus for $1.5 million SEC offering - scanx.trade
1.5M-share resale puts dilution on table at Acurx (ACXP). How much cash can it still tap? - Stock Titan
Acurx Pharmaceuticals, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Acurx (ACXP) Q1 2026 Earnings: Profit Per Share Clears Its Benchmark for the Current Session; After Earnings: The Market Price Moves 1.38% Higher in the Latest ReadingProfit Growth Outlook - dars.gov.et
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ... - Yahoo Finance
Acurx (ACXP) Price-Move Recap: Ends Down by 12.73% at $1.44 in the Latest Reading; Key Levels - vinanet.vn
Acurx Pharmaceuticals Receives FDA Conditional Acceptance - TradingView
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP) - The Globe and Mail
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Acurx beats Q2 2026 EPS forecast but shares slip premarket - Investing.com Nigeria
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView
Acurx Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 3ZO0 | US00510M2035 - marketscreener.com
Acurx Pharmaceuticals, Inc.: Target Price Consensus and Analysts Recommendations | ACXP | US00510M2035 - marketscreener.com
Acurx Pharmaceuticals Q2 Results: EPS misses estimate, losses widen - scanx.trade
Acurx Pharmaceuticals reports Q2 2026 results, advances antibiotic trials, and strengthens patent portfolio. - Pluang
Acurx Q2 2026 earnings: per-share loss narrows as share count rises - TradingKey
Acurx Receives Conditional FDA Acceptance for C. difficile Drug Name - Stock Titan
ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView
Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan
Acurx Pharmaceuticals Inc (ACXP) Debt 2025 - stocktitan.net
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
New patents cover Acurx antibiotics targeting DNA Polymerase IIIC - Stock Titan
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics - Yahoo Finance
Acurx and Leiden Researchers Seek 3D Structure to Guide MRSA Antibiotics - Stock Titan
Acurx Pharmaceuticals, Inc. and Leiden University Medical Center Announce Scientific Partnership to Advance Development of Dna Polymerase IIIC Inhibitor Antibiotics - marketscreener.com
ACXP Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Acurx Pharmaceuticals Inc (ACXP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program - TradingView
FDA Provides Further Regulatory Guidance to A - Moomoo
Acurx's ~550-Patient Trial Could Support C. diff Treatment, Recurrence Reduction - Stock Titan
Acurx Pharmaceuticals FDA open to single Phase 3 trial for ibezapolstat NDA - scanx.trade
ACXP Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Continued R&D ExecutionEarnings Stability Report - vinanet.vn
ACXP Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline at a Pre-Revenue Stage - vinanet.vn
Acurx Pharmaceuticals Inc (ACXP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.480|Chg%:-0.060 - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.395|Chg%:-0.085 - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Institutional Confidence - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Valuation: PE, PB & Fair Value Analysis - tradingkey.com
TradingKey - TradingKey
Acurx Pharmaceuticals Inc (ACXP) Cash Flow - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.435|Chg%:+0.015 - TradingKey
ACXP|Acurx Pharmaceuticals Inc|Price:1.450|Chg%:+0.010 - TradingKey
Acurx Pharmaceuticals (ACXP) Income Statement & Earnings - Moomoo
ACXP Q1 2026 Earnings: EPS Beats Estimates Amid Pre-Revenue Period, Stock Declines Moderately - vinanet.vn
Acurx Pharmaceuticals (ACXP) Registration filing Summary - Quartr
Acurx Pharmaceuticals (ACXP) upgraded to buy: Here's why - MSN
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection - Yahoo Finance Singapore
Price to earnings forward of Acurx Pharmaceuticals, Inc. – NASDAQ:ACXP - TradingView
Acurx Pharmaceuticals Inc. (ACXP) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update - Yahoo Finance
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference - AOL.com
Acurx Pharmaceuticals (ACXP) Slides 8.23% as Stock Tests Key Support at $1.38Relative Volume - dars.gov.et
Acurx Pharmaceuticals outlines its antibiotic pipeline as investors weigh long-term prospects - Ad-hoc-news.de
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):